Trials / No Longer Available
No Longer AvailableNCT00508963
Compassionate Use of Sodium Stibogluconate (Pentostam) for Cutaneous and Mucocutaneous New World Leishmaniasis
- Status
- No Longer Available
- Phase
- —
- Study type
- Expanded Access
- Enrollment
- —
- Sponsor
- University of California, San Francisco · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- —
Summary
Patients with biopsy proven new world cutaneous or mucocutaneous leishmaniasis will be treated with sodium stibogluconate (Pentostam).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | sodium stibogluconate (Pentostam) | 20 mg/kg IV every day for 20 or 28 days |
Timeline
- First posted
- 2007-07-30
- Last updated
- 2023-12-27
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT00508963. Inclusion in this directory is not an endorsement.